Target intelligence / Profile preview

Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 (MT-ND3)

Target
MT-ND3
Molecular classification
Enzyme, Respiratory chain complex I core subunit, Mitochondrial protein
01

Overview

Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 (MT-ND3) is a core subunit of respiratory chain complex I, the largest enzyme complex of the mitochondrial electron transport system. MT-ND3 is essential for the catalytic activity of complex I, which transfers electrons from NADH to ubiquinone, contributing to the generation of the proton gradient and ATP synthesis in mitochondria. Variants in MT-ND3 cause inherited mitochondrial diseases such as Leigh syndrome and Leber hereditary optic neuropathy and are implicated in Parkinson's disease. MT-ND3 itself is not a classic drug target, but is crucial in the function and dysfunction of the mitochondrial respiratory chain, and is important for diagnosis and study of mitochondrial diseases.

Other names
NADH-ubiquinone oxidoreductase chain 3MTND3NADH3ND3NAD3NADH dehydrogenase subunit 3complex I ND3 subunit
02

Mechanism of action

Inhibition of mitochondrial respiratory chain complex I, disruption of electron transport, and reduction of NADH oxidation can occur with inhibitors of complex I (e.g., rotenone acts by direct inhibition of site within complex I)

03

Biological functions

Mitochondrial electron transport (NADH to ubiquinone)Oxidative phosphorylationNADH dehydrogenase (ubiquinone) activity
04

Disease associations

Mitochondrial complex I deficiencyLeigh syndromeLeber hereditary optic neuropathyParkinson's disease
05

Safety considerations

Toxicity or mitochondrial dysfunction risk when complex I is inhibited or mutateddefects can cause severe energy failure in high-energy tissues (e.g., brain, muscle)clinical syndromes are often severe and multisystemic
06

Interacting drugs

No direct approved drugs target MT-ND3 itself; however, drugs interfering with mitochondrial complex I (e.g., metformin, rotenone, piericidin A) impact its function as part of the complex
07

Biomarkers

MT-ND3 mutations or dysfunction serve as genetic and functional biomarkers in mitochondrial disorders, including Leigh syndrome, Leber hereditary optic neuropathy, and Parkinson's disease

Beyond the preview

Go deeper on Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 (MT-ND3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3 (MT-ND3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call